886503-11-3

Basic information

• Product Name: 2-(3,5-DIFLUORO-PHENYL)-PYRROLIDINE
• Synonyms: 2-(3,5-DIFLUORO-PHENYL)-PYRROLIDINE
• CAS NO: 886503-11-3
• Molecular Formula: C₁₀H₁₁F₂N
• Molecular Weight: 183.2
• Mol File: 886503-11-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 221℃
• Flash Point: 88℃
• Appearance: /
• Density: 1.164
• CAS DataBase Reference: 2-(3,5-DIFLUORO-PHENYL)-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,5-DIFLUORO-PHENYL)-PYRROLIDINE(886503-11-3)
• EPA Substance Registry System: 2-(3,5-DIFLUORO-PHENYL)-PYRROLIDINE(886503-11-3)

Safety Data

• Hazardous Substances Data: 886503-11-3(Hazardous Substances Data)

Usage

General Description

2-(3,5-difluoro-phenyl)-pyrrolidine is a chemical compound that belongs to the class of pyrrolidine derivative. It is a white to off-white solid that is commonly used in the pharmaceutical industry as a building block for the synthesis of various bioactive compounds. This chemical has potential antiviral and antibacterial activities and is being studied for its potential therapeutic applications. 2-(3,5-difluoro-phenyl)-pyrrolidine plays a crucial role in the development of new pharmaceuticals and has the potential to be a valuable tool for medicinal chemistry research. It is important for drug discovery and development efforts, and its unique structure and properties make it a valuable compound in the field of medicinal chemistry and pharmacology.

Upstream product

• 64248-63-1 3,5-difluorobenzonitrile 
• 455-40-3 3,5-difluorobenzoic acid 
• 350-19-6 ethyl 3,5-difluorobenzoate 

Relevant articles and documents

Rational drug design to explore the structure-activity relationship (SAR) of TRK inhibitors with 2,4-diaminopyrimidine scaffold

Tropomyosin receptor kinase (TRK) is an ideal target for treating cancers caused by the NTRK gene fusion. In this study, more than 60 2,4-diaminopyrimidine derivatives were prepared to understand the structure-activity relationship and confirm the rationality of the pharmacophore model reported previously. Among them, compound 19k was found to be a potent pan-TRK inhibitor that inhibits the proliferation of Km-12 cell lines. Additionally, compound 19k induced the apoptosis of Km-12 cells in a concentration-dependent manner. Western blot analysis revealed that compound 19k inhibited the phosphorylation of TRK to block downstream pathways. Compound 19k also possessed outstanding plasma stability and liver microsomal stability in vitro, with half-lives greater than 289.1 min and 145 min, respectively. Pharmacokinetic studies indicated that the oral bioavailability of compound 19k is 17.4%. These results demonstrate that compound 19k could serve as a novel lead compound for overcoming NTRK-fusion cancers.